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Introduction {#sec1}
============

Epithelial morphogenesis contributes to organogenesis, functional formation, and regeneration, which play a fundamental role in animal development ([@bib37], [@bib46]). The mammary gland consists of a highly branched ductal epithelium surrounded by fatty stroma. Unlike other organs, mammary gland ductal epithelium morphogenesis is predominantly active after the onset of puberty ([@bib47]). The mammary epithelial morphogenesis involves the reiterative process of ductal branching and invasion into the surrounding mesenchyme, which is the base of organotypic growth of mammary parenchyma and important for functional formation ([@bib21], [@bib28], [@bib47]). Pubertal mammary gland is a good model that is utilized to study the molecular mechanisms of epithelial morphogenesis ([@bib12], [@bib23], [@bib25]).

The development and functional formation of mammary gland are vital for providing offspring nutrition and milk production. It undergoes several distinct stages including embryonic, neonatal, pubertal, pregnant, lactational, and involutional stages ([@bib27]). Specialized structures named terminal end buds (TEBs) are formed at the end of growing ducts in pubertal mammary, which drives ductal branching morphogenesis and lumen formation by a highly regulated process of cell proliferation and death ([@bib14], [@bib48]). TEBs contain an outer layer of cap cells, which give rise to myoepithelial cells and multilayered body cells, which are the progenitors of luminal cells ([@bib11]). Up to adult, the TEBs stop elongating and revert to simple epithelial architecture when they reach the edges of mammary fat pad and give rise to mature ductal tree ([@bib28], [@bib47]). Mature ducts consist of two differentiated epithelial cell types, both deriving from a multipotent progenitor population. Myoepithelial cells present at the outer layer of the ducts form a sleeve around the primary ducts, and luminal epithelial cells situate in ductal lumen and secrete milk proteins ([@bib13], [@bib38], [@bib45]). The process of mammary epithelial morphogenesis and functional formation requires cell differentiation, proliferation, and apoptosis ([@bib6], [@bib19], [@bib22]). However, the underlying mechanisms of mammary epithelial morphogenesis remain unclear.

Cysteine dioxygenase (CDO) and cysteine sulfinic acid decarboxylase (CSAD), two key enzymes in cysteine oxidative metabolism and taurine biosynthesis, are present in the mammary gland ([@bib44]). CDO is a mononuclear iron-dependent enzyme that catalyzes the oxidation of L-cysteine into cysteine sulfinic acid (CSA) ([@bib7], [@bib24], [@bib39]). CDO controls the intracellular content of cysteine and the diversity of sulfureted compounds in the body ([@bib42], [@bib49]). CSA can be decarboxylated by CSAD to form hypotaurine and is eventually oxidized into taurine ([@bib30]). The activity of CDO has important medical implications in Parkinson and Alzheimer diseases, systemic lupus erythematosus, and rheumatoid arthritis ([@bib8], [@bib10]). In addition, CDO inactivation is associated with occurrences of various cancers ([@bib3], [@bib16], [@bib26]). Whether the process of cysteine oxidative metabolism is involved in the mammary epithelial morphogenesis is still unknown. In this study, we found that CDO is highly enriched during mammary branching morphogenesis and localizes in body cells of TEBs and luminal epithelial cells in mature ducts. By mutation of CDO and CSAD we showed that CDO is necessary for mammary epithelial morphogenesis and maintenance of luminal epithelial differentiation and regeneration.

Results {#sec2}
=======

CDO Is Highly Enriched in the Mammary Gland during Ductal Branching Morphogenesis {#sec2.1}
---------------------------------------------------------------------------------

We initially determined the expression profile of CDO in various tissues of 6-week-old female mouse by reverse-transcriptase polymerase chain reaction (PCR) ([Table S1](#mmc1){ref-type="supplementary-material"}) and western blot (WB). The results showed that CDO transcription existed in all detected tissues; CDO expression was high in the liver, mammary gland, lung, and kidney, at both the mRNA and protein levels, but very low in the endocrine organs, including the hypothalamus, pituitary, and ovary of 6-week-old female mice ([Figures 1](#fig1){ref-type="fig"}A and 1B). During mammary gland development, CDO was abundant in the mammary gland of 21-day-old, 6-week-old, and 12-week-old virgin mice as well as in mice mammary gland of involution phase. In contrast, CDO was very low in the mammary gland of pregnant and lactating mice ([Figures 1](#fig1){ref-type="fig"}C and 1D). CSAD displayed similar expression profile to that of CDO ([Figures 1](#fig1){ref-type="fig"}C and 1D). These results indicated that CDO was enriched in mammary gland during ductal branching morphogenesis (e.g., puberty, non-pregnant, and non-lactating adult), but had low expression in alveolus stage (pregnant and lactating stage). We also determined the localization of CDO in mammary gland by immunohistochemistry. The results showed that CDO mainly localized to the luminal epithelial cells of mature duct ([Figure 1](#fig1){ref-type="fig"}F) and body cells of TEBs ([Figure 1](#fig1){ref-type="fig"}E) in 6-week-old mouse mammary. These data suggest that CDO in the mammary gland may be associated with mammary epithelial morphogenesis.Figure 1Expression of CDO in Mouse Mammary Gland(A) CDO mRNA expression in various tissues of 6-week-old female mouse by RT-PCR.(B) CDO protein production in various tissues of 6-week-old female mouse by western blot.(C) The expression profile of CDO and CSAD mRNAs in mammary gland of different developmental stages.(D) The production of CDO and CSAD proteins in mammary gland of different developmental stages.(E) CDO localization in TEBs of pubertal mammary gland by immunohistochemistry (IHC) (brown stain).(F) CDO localization in mature ducts of mammary gland by IHC (brown stain).Scale bar = 50 μm.

CDO Is Required for Mammary Development {#sec2.2}
---------------------------------------

To reveal the biological function of CDO and CSAD in mammary gland, we generated CDO knockout (KO) mice and CSAD KO mice via injection of SpCas9n (D10A) mRNA and a pair of single guide RNAs (sgRNAs) ([Table S2](#mmc1){ref-type="supplementary-material"}) into mouse zygotes, as described in a previous study ([@bib32], [@bib33]). Multiple mutant lines were confirmed by PCR and Sanger sequencing ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B, [Table S3](#mmc1){ref-type="supplementary-material"}). A CDO KO mutant line with 83-nucleotide deletion in the first exon of mouse CDO and a CSAD KO mutant line with 32-nucleotide deletion in the second exon of mouse CSAD were used in the following experiments ([Figures 2](#fig2){ref-type="fig"}A, 2B, [3](#fig3){ref-type="fig"}A, and 3B). Lack of CDO and CSAD proteins in KO mutant was verified by WB of mammary gland lysate ([Figures 2](#fig2){ref-type="fig"}C and [3](#fig3){ref-type="fig"}C). Both CDO KO and CSAD KO mice exhibited systematic taurine deficiency ([Figures 2](#fig2){ref-type="fig"}D and [3](#fig3){ref-type="fig"}D). We also observed that CDO KO mice had the phenotype of joint contracture at forelimb ([Figure S1](#mmc1){ref-type="supplementary-material"}C), which was consistent with a previous report ([@bib43]). In addition, CDO KO mice tend to have more large alveoli, which may result in decreased total alveoli number and alveolar surface area ([Figure S1](#mmc1){ref-type="supplementary-material"}D).Figure 2Generation and Confirmation of CDO KO Mice(A) Murine CDO gene structure and Cas9n target information. The start codon of CDO (ATG) in the first exon is indicated in the black box. Two sgRNAs sequences are underlined, and PAM is indicated in red.(B) After microinjection of the mixture of SpCas9n (D10A) mRNA (60 ng/μL) and sgRNAs (25 ng/μL) into cytoplasm of 0.5 dpc (days post-coitum) embryos, they were transferred to the oviduct of a pseudopregnant female. The F0 generation mice were genotyped by PCR and Sanger sequencing of targeted region. A mutation line of 83-nucleotide deletion (Δ83) in the codon region of CDO, which led to frameshift in protein sequence, was determined.(C) CDO mutation was verified by western blot of wild-type (WT), CDO Δ83 heterozygote (CDO Het), and CDO Δ83 homozygote (CDO KO) mammary gland lysates (n = 2 mammary per genotype).(D) Serum taurine levels of WT (n = 4), CDO Het (n = 4), and CDO KO (n = 4) mice assayed by high-performance liquid chromatography. CDO KO mice showed 82% reduction of serum taurine compared with WT (0.21± 0.11 versus 1.18 ± 0.16 mM) (t test, t-value = 7.855, p = 0.004).Figure 3Generation and Confirmation of CSAD KO Mice(A) Murine CSAD gene structure and Cas9n target information. ATG in red is the start codon of CSAD in the second exon followed by two truncated Cas9n targets (sgRNAs\' spacer in blue and PAM in green).(B) After microinjection of SpCas9n (D10A) mRNA (60 ng/μL) and sgRNAs (25 ng/μL) into cytoplasm of 0.5 dpc (days post-coitum) embryos, they were transferred to the oviduct of a pseudopregnant female. The F0 generation mice were genotyped by PCR and Sanger sequencing of target region. A mutation line of 32-nucleotide deletion (Δ32) in codon region of CSAD, which leads to frameshift in protein sequence, was determined.(C) CSAD mutation verified by western blot of WT, CSAD Δ32 heterozygote (CSAD Het), and CSAD Δ32 homozygote (CSAD KO) mammary gland protein (n = 2 mammary per genotype).(D) Serum taurine level of WT (n = 4), CSAD Het (n = 4), and CSAD KO (n = 4) mice were determined by high-performance liquid chromatography. CSAD KO mice showed 78% reduction of serum taurine compared with WT (0.26 ± 0.12 versus 1.12 ± 0.13 mM) (t test, t-value = 9.025, p = 0.003) ∗∗p\<0.01.

We subsequently carried out whole-mount analysis of the fourth mammary gland from wild-type (WT), CSAD KO, and CDO KO virgin female mice in different developmental stages. Compared with WT mammary, CSAD KO mammary developed normally and had no significant difference in ductal elongation and branching ([Figures 4](#fig4){ref-type="fig"}A and 4B). In contrast, CDO KO mammary showed severe impairment in mammary development of ductal branching morphogenesis and elongation ([Figure 4](#fig4){ref-type="fig"}C). The mammary ductal elongation of TEBs exceeded the lymph node and generated a lot of branches in 42-day-old WT and CSAD KO mice, but in CDO KO mammary the duct TEBs could not reach the lymph node and branches were rather few. At the age of 12 weeks, the duct invaded into the fat pad and was bestrewed in WT and CSAD KO mice, whereas in CDO KO mammary, the duct just reached the lymph node and the branches were far from filling the fat pad. The ducts were not capable of filling the mammary fatty stroma by 24 weeks postpartum in CDO KO mice ([Figure 4](#fig4){ref-type="fig"}C). CDO heterozygous (CDO Het) mammary showed no obvious defect in ductal morphogenesis within the age of 12 weeks ([Figure 4](#fig4){ref-type="fig"}D). Quantitative analysis was carried out on the length of ductal invasion and the number of branches and TEBs. It showed that the duct invasion in the stroma of CDO KO mammary was much slower than that of WT and CSAD KO mice at age 42 days and 12 weeks ([Figure 4](#fig4){ref-type="fig"}E). Both the number of branches and TEBs were extremely low in CDO KO females compared with WT and CSAD KO mice ([Figures 4](#fig4){ref-type="fig"}F and 4G). We determined pituitary growth hormone (GH) and prolactin (PRL) by WB; the results indicated that CDO did not influence the synthesis of GH and PRL ([Figure S2](#mmc1){ref-type="supplementary-material"}). CDO KO females were fertile, got pregnant properly, and gave birth at term with normal litter size ([Table S4](#mmc1){ref-type="supplementary-material"}). To rule out the effect of lack of CDO in other organs, we carried out adeno-associated virus (AAV)-mediated mammary-gland-specific expression and KO CDO by *in situ* injection of AAV into the fourth mammary gland. AAV serotype 2 was used in this study. Mouse CDO expression and control AAV vector were constructed for packaging AAV ([Figure S3](#mmc1){ref-type="supplementary-material"}A). The CDO KO mice were injected with CDO expression AAV or control AAV subcutaneously at the site of the fourth mammary nipple at the age of P10 for CDO rescue in mammary gland. The validity of the CDO expression and control AAV was determined by detecting green fluorescence and CDO expression assay in the mammary gland 2 weeks after injection. It showed strong green fluorescence and rescued CDO expression in the mammary ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Whole-mount analysis of the mammary indicated that rescue of CDO expression in mammary significantly improved ductal elongation, branching, and TEB number at P42 ([Figures 4](#fig4){ref-type="fig"}H, 4I, 4L--4N). The previously described AAV vector pX601 ([@bib31]) was used to package CDO KO (constructed with an sgRNA spacer) or control (without sgRNA) AAV ([Figure S3](#mmc1){ref-type="supplementary-material"}D). For high efficiency of SaCas9-mediated CDO KO in mammary gland, the AAVs with two highly specific SaCas9 targets of mouse CDO were mixed for injection ([Table S5](#mmc1){ref-type="supplementary-material"}). The CDO Het females were injected with a CDO KO AAV (SaCas9 with sgRNA) or control AAV (SaCas9 without sgRNA) subcutaneously at the site of the fourth mammary nipple at the age of P10. The CDO expression in the mammary gland was determined after 2 weeks of first injection. It showed significant decrease of CDO expression in the mammary ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Whole-mount analysis of the mammary indicated that KO of CDO by AAV-Cas9-sgRNA injection in the mammary significantly influenced ductal morphogenesis ([Figures 4](#fig4){ref-type="fig"}J, 4K, and 4O--4Q), which confirmed the function of CDO in mammary development. These data suggest that CDO in mammary gland is involved in ductal branching morphogenesis.Figure 4Loss of CDO Causes Mammary Developmental Defect in Ductal Invasion and Branching(A--D) Carmine-stained fourth mammary gland whole-mount of (A) WT (n = 4 mammary per time point), (B) CSAD KO (n = 4 mammary per time point), (C) CDO KO (n = 5 mammary per time point), and (D) CDO Het (n = 4 mammary per time point) mice at different age of ducts morphogenesis.(E) Length of ductal invasion (represented as distance from initial point of primary duct to distal TEBs or far end of the primary duct) in WT, CSAD KO, and CDO KO mammary glands at different ages (WT versus CDO KO, t test: 42 days, t-value = 11.889, p = 0.001; 12 weeks, t-value = 13.175, p = 0.001).(F) Number of TEBs in 42-day-old WT, CSAD KO, and CDO KO mammary glands (WT versus CDO KO, t test: t-value = 7.419, p = 0.005).(G) Number of branches in WT, CSAD KO, and CDO KO mammary glands at different ages (WT versus CDO KO, t test: 42 days, t-value = 7.527, p = 0.005; 12 weeks, t-value = 7.924, p = 0.004).(H and I) Carmine-stained fourth mammary gland whole-mount duct morphogenesis of 42-day-old CDO KO mice with injection of control AAV (AAV-GFP) into one side of fourth mammary (H) and CDO expression AAV (AAV-CDO) into another side (I) at the age of P10 (n = 4).(J and K) Carmine-stained fourth mammary gland whole-mount duct morphogenesis of 42-day-old CDO Het mice with injection of SaCas9 control AAV (AAV-Cas9) into one side of fourth mammary (J), and SaCas9-sgRNA AAV (AAV-Cas9-sgRNAs) into another side (K) at the age of P10 (n = 4).(L) Number of TEBs in the mammary gland injection with CDO expression AAV (AAV-GFP versus AAV-CDO t test: t-value = −7.905, p = 0.004).(M) Number of branches in the mammary gland injection with CDO expression AAV (AAV-GFP versus AAV-CDO t test: t-value = 6.563, p = 0.007).(N) Length of ductal invasion in the mammary gland injection with CDO expression AAV (AAV-GFP versus AAV-CDO t test: t-value = −10.205, p = 0.002).(O) Number of TEBs in the mammary gland injection with Cas9-sgRNA AAV (AAV-Cas9 versus AAV-Cas9-sgRNA t test: t-value = 3.759, p = 0.033).(P) Number of branches in the mammary gland injection with Cas9-sgRNA AAV (AAV-Cas9 versus AAV-Cas9-sgRNA t test: t-value = 4.516, p = 0.02).(Q) Length of ductal invasion in the mammary gland injection with Cas9-sgRNA AAV (AAV-Cas9 versus AAV-Cas9-sgRNA t test: t-value = 3.576, p = 0.037). Scale bar, 2 mm. \* represents significant difference with control (p \< 0.05), \*\* represents significant difference with WT or control (p \< 0.01).

We examined the microstructure of mammary gland in CDO KO, CSAD KO, and WT mice by hematoxylin and eosin (H&E) stain. The results showed that the tissue structure was mainly normal in 42-day-old CDO KO and CSAD KO mammary of mature ducts and TEBs with well-organized epithelial cells in the ducts ([Figures 5](#fig5){ref-type="fig"}A--5F), but that a disorganized and detached multilayered luminal epithelium developed in ducts in 12-week-old CDO KO mammary and also that there was disruption of the ductal architecture ([Figures 5](#fig5){ref-type="fig"}G--5I). In addition, we observed that CDO mutant females had a higher risk of breast tumors at the age of 12 weeks. We occasionally observed that CDO KO and CDO heterozygote mice got breast tumor, but no case was found in other genotypes ([Figure S4](#mmc1){ref-type="supplementary-material"}). These results suggest that CDO is required to maintain lumen and cell viability of epithelium in mammary.Figure 5Microstructure Analysis of CDO KO Mammary GlandHematoxylin and eosin (H&E) staining of paraffin-embedded sections of murine mammary gland.(A--C) Microstructure of mature ducts in 42-day-old (A) WT, (B) CSAD KO, and (C) CDO KO mice mammary glands (n = 4 mammary per treatment).(D--F) Microstructure of TEBs in 42-day-old (D) WT, (E) CSAD KO, and (F) CDO KO mice mammary glands (n = 4 mammary per treatment).(G--I) Microstructure of mature ducts in 12-week-old (G) WT, (H) CSAD KO, and (I) CDO KO mice mammary glands (n = 4 mammary per treatment). Scale bar, 50 μm.

Loss of CDO Leads to Lactation Insufficiency {#sec2.3}
--------------------------------------------

We found that both CDO KO and CSAD KO mice can get pregnant mating with a WT male and give birth at term. However, the offspring of CDO KO mother grew retardedly and tended to die before weaning, in contrast to the offspring of CSAD KO mother, which grew well in the pre-weaning period. Whole-mount and microstructure analysis of the mammary gland in lactation period revealed that the mammary gland of CSAD KO mothers developed normally, even with more intensive mammary gland alveolus compared with WT ([Figures 6](#fig6){ref-type="fig"}C and 6D). However, CDO KO mothers exhibited severe defects in lactation such as reduction in the number and size of milk-producing alveolar units ([Figures 6](#fig6){ref-type="fig"}E and 6F) compared with WT mothers ([Figures 6](#fig6){ref-type="fig"}A and 6B). Owing to the lactation defect, the offspring of CDO KO mothers displayed a significant reduction in weight during suckling period, and they were apt to die at day 15 postpartum. When nursing them with a WT foster mother, the offspring of CDO KO mothers grew normally, and almost all of them survived to weaning ([Figures 6](#fig6){ref-type="fig"}G and 6H). These data suggest that loss of CDO results in poor lactation performance, which could be the consequence of developmental defects in mammary duct branching morphogenesis.Figure 6Loss of CDO Resulted in Reduction of Mammary Alveolar and Lactation Insufficiency(A-F) Whole mount of mammary gland at lactation day 7 (L7) of (A) WT (n=4), (C) CSAD KO (n=4), and (E) CDO KO (n=4) mice. Scale bar represents 5mm. Mircro-structure of mammary gland at L7 of (B) WT, (D) CSAD KO, and (F) CDO KO mice, performed by paraffin section and HE staining.(G) Survival rate of the offspring from CDO KO mothers during suckling period by foster (n = 24) or self-feeding (n = 49). \* represents significant difference of survival rate between CDO KO mother self-feeding offspring and foster offspring (χ^2^ test, p = 0.0269).(H) Growth curve of the offspring of CDO KO mother during suckling period by foster (n = 24) or self-feeding (n = 49). Significant difference of body weight between CDO KO mother self-feeding offspring and foster offspring marked with \* (t test, \*p \< 0.05, \*\*p \< 0.01).

CSA Supplementation Rescues the Ductal Branching Morphogenesis of CDO KO Mice and Promotes Mammary Development of WT Mice {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------

As a major catabolic enzyme of cysteine catabolism, CDO catalyzes by adding dioxygen to cysteine to form CSA ([@bib17], [@bib24], [@bib39]). CSA is decarboxylated by CSAD to form hypotaurine, which is subsequently oxidized into taurine spontaneously in cells ([@bib41]) ([Figure 7](#fig7){ref-type="fig"}A). We measured CSA levels in the serum and mammary gland of WT, CDO KO, and CSAD KO mice using high-performance liquid chromatography. The result showed that CSA was almost not detected in any tissue of CDO KO mice, but that it increased in CSAD KO mice, both in serum and mammary tissue compared with WT ([Figures 7](#fig7){ref-type="fig"}B and 7C). According to cysteine-metabolizing pathway, CDO deletion will lead to deficiency of CSA and taurine along with cysteine accumulation in the cells ([@bib18], [@bib41], [@bib42], [@bib43]). We hypothesized that mammary dysplasia in CDO KO mice may be caused by CSA and taurine deficiencies or cysteine toxicity. We attempted to create intracellular cysteine excess by cysteine-Cl supplementation (200 mg/kg body weight) via intraperitoneal (i.p.) injection once a day (q.d.) or by 0.5% (w/v) cysteine-Cl supply in drinking water from 21 days postpartum (P21) to P41 in WT mice. We also supplemented the CDO KO mice with CSA (50 or 100 mg/kg body weight) or taurine (100 mg/kg body weight) from P21 to P41 q.d. via i.p. injection. Equal volume (10 mL/kg body weight) of NaCl solution (0.8% w/v) was injected q.d. into WT and CDO KO females as control. After 21-day treatment, their fourth mammary glands were collected and whole-mount analysis was performed. The results showed that neither injection nor supplementation of cysteine-Cl in drinking water showed obvious impact on mammary ductal development in WT mice ([Figures 7](#fig7){ref-type="fig"}D, 7E, 7G--7I, and [S5](#mmc1){ref-type="supplementary-material"}). In contrast, CSA supplementation promoted mammary ductal elongation and branching in a dose-dependent manner ([Figures 7](#fig7){ref-type="fig"}J--7L and 7N--7P). The ductal branching morphogenesis can be almost restored in CDO KO mice when treated with CSA at a dose of 100 mg/kg body weight ([Figures 7](#fig7){ref-type="fig"}L and 7N--7P). Taurine showed little influence on ductal elongation and branching ([Figures 7](#fig7){ref-type="fig"}M--7P). All mice injected with excess dosage of CSA (200 mg/kg body weight) became unhealthy and died within 2 weeks of treatment, indicating that CSA can be toxic. In addition, whole-mount analysis of CSAD KO mammary revealed that lack of taurine had little influence on mammary ductal branching morphogenesis ([Figure 4](#fig4){ref-type="fig"}B), consistent with our data that taurine supplementation did not restore the mammary ductal branching morphogenesis of CDO KO mice. CSA supplementation also promoted mammary development in WT mice ([Figures 7](#fig7){ref-type="fig"}F--7I). All these results suggested that CSA may be the key molecule through which CDO regulates mammary gland development.Figure 7CSA Supplementation Rescues Mammary Duct Branching Morphogenesis of CDO KO Mice(A) Pathway of cysteine oxidative metabolism.(B) Serum CSA level of WT (n = 4), CDO KO (n = 4), and CSAD KO (n = 4) mice assayed by high-performance liquid chromatography. CDO KO mice showed significant reduction of serum CSA compared with WT (0.02 ± 0.007 versus 0.202 ± 0.044 mM) (t test, t-value = 7.342, p = 0.005) and CSAD KO mice showed increased serum CSA compared with WT (0.339 ± 0.072 versus 0.202 ± 0.044 mmol/L) (t test, t-value = −5.717, p = 0.011).(C) CSA levels in mammary tissue of WT (n = 4), CDO KO (n = 4), and CSAD KO (n = 4) mice. Similar to serum level, CSA was deficient in CDO KO mammary, but increased in CSAD KO mammary (WT 2.37 ± 0.467, CDO KO 0.21 ± 0.097, CSAD KO 3.79 ± 0.434 mmol/kg) (WT versus CDO KO, t test, t-value = 7.713, p = 0.005; WT versus CSAD KO, t test, t-value = −4.212, p = 0.024).(D--F and J--M) The fourth mammary whole mount from 42-day-old WT or CDO KO mice with different treatments from P21 to P41. (D) Mammary collected from WT mice supplemented with 0.8% (w/v) NaCl (10 mL/kg body weight/day) as a control (n = 4). (E) Mammary collected from WT mice supplemented with cysteine-Cl (200 mg/kg body weight/day i.p.) (n = 4). (F) Mammary collected from WT female supplemented with CSA (100 mg/kg body weight i.p. q.d.) (n = 4). (J) Mammary collected from CDO KO mice supplemented with 0.8% NaCl (10 mL/kg body weight/day i.p.) as a control (n = 4). (K) Mammary collected from CDO KO mice supplemented with CSA (50 mg/kg body weight/day i.p.) (n = 4). (L) Mammary collected from CDO KO mice supplemented with CSA (100 mg/kg body weight/day i.p.) (n = 4). (M) Mammary collected from CDO KO mice supplemented with taurine (100 mg/kg body weight/day i.p.) (n = 4).(G--I) Influence of cysteine-Cl and CSA supplementation on (G) TEB number (t test, NaCl versus CSA, t-value = −3.196, p = 0.049), (H) ductal branch number (t test, NaCl versus CSA, t-value = −3.836, p = 0.031), and (I) ductal invasion length (t test, NaCl versus CSA, t-value = −3.411, p = 0.042) of WT mice mammary gland (the quantitative analysis of B--D).(N--P) Influence of CSA and taurine supplementation on (N) TEB number (t test, NaCl versus CSA 50, t-value = −7.687, p = 0.025; NaCl versus CSA100, t-value = −9.276, p = 0.003; NaCl versus Tau100, t-value = −2.777, p = 0.069), (O) ductal invasion length (t test, NaCl versus CSA 50, t-value = −3.932, p = 0.029; NaCl versus CSA100, t-value = −5.342, p = 0.031; NaCl versus Tau100, t-value = −2.906, p = 0.062), and (P) ductal branch number (t test, NaCl versus CSA 50, t-value = −7.000, p = 0.006; NaCl versus CSA100, t-value = −6.755, p = 0.007; NaCl versus Tau100, t-value = −2.333, p = 0.102) of CDO KO mice mammary gland (the quantitative analysis of J--M). Scale bar, 2 mm. \* represents significant difference compared with control (t test, p \< 0.05), \*\* represents significant difference compared with control (t test, p \< 0.01).

CDO Plays a Role in Retaining Lumen Character and Maintaining Luminal Cell Differentiation {#sec2.5}
------------------------------------------------------------------------------------------

To characterize the consequences of CDO deletion in the pubertal mammary gland, we immunostained the mammary glands with luminal epithelial and myoepithelial cell markers. The results showed that positive signals of luminal epithelial-cell-specific marker keratin 8 (K8) and E-cadherin (E-Cadh) located in mammary luminal epithelial cells, and it appeared that no distinct difference was observed among WT, CSAD KO, and CDO KO mammaries ([Figures 8](#fig8){ref-type="fig"}A and 8B). Co-immunostaining with the luminal epithelial cell marker keratin 18 (K18) and the myoepithelial marker keratin 14 (K14) revealed that luminal epithelial cells were exclusively K18 positive in all three types of mammary. K14 was exclusively present in myoepithelial cells of WT and CSAD KO mammary. However, in CDO KO mammary, K14 was present not only in myoepithelial cells but also in luminal cells with relatively weaker signal ([Figure 8](#fig8){ref-type="fig"}C). It suggested that loss of CDO leads to the luminal cell showing certain characteristics of myoepithelial cells. To clarify whether the luminal cells were transduced into myoepithelial cell in CDO KO mammary, the myoepithelial cell characteristic protein α-smooth muscle actin (α-SMA) was further detected. It revealed that α-SMA was distinctively expressed in myoepithelium and was negative in luminal epithelial cells in all three types of mammaries ([Figure 8](#fig8){ref-type="fig"}D). CSA supplementation increased K14 expression slightly in myoepithelial cells, but reduced K14 expression in luminal epithelial. Taurine supplementation had little effect on K14 expression ([Figure 8](#fig8){ref-type="fig"}E). CSA and taurine supplementation had no effect on α-SMA distribution ([Figure S6](#mmc1){ref-type="supplementary-material"}). In addition, estrogen receptor alpha (ERα) distribution in luminal epithelium showed no difference among three genotypes of mice ([Figure S7](#mmc1){ref-type="supplementary-material"}).Figure 8CDO Loss Changed Luminal Cell Character(A) Immunostaining of E-cadherin (E-Cadh) in WT, CSAD KO, and CDO KO mammaries (n = 4).(B) Immunostaining of keratin 8 (K8) in WT, CSAD KO, and CDO KO mammaries (n = 4).(C) Co-immunostaining with the luminal epithelial cell marker keratin 18 (K18) and the myoepithelial marker keratin 14 (K14) in WT, CSAD KO, and CDO KO mammaries (n = 4). White coarse arrowhead points to myoepithelium, and white speculate arrowhead points to luminal epithelium (n = 4).(D) Immunostaining of α-smooth muscle actin (α-SMA) in WT, CSAD KO, and CDO KO mammaries (n = 4).(E) Co-immunostaining with K18 and K14 in CDO KO mice mammary gland supplemented with NaCl, taurine, or CSA (n = 4). White coarse arrowhead points to myoepithelium, and white speculate arrowhead points to luminal epithelium.(F) Relative expression of E-Cdh, K8, K18, and K14 proteins in WT, CSAD KO, and CDO KO mammaries (n = 4).(G) Influence of taurine and CSA supplementation on E-Cdh, K18, and K14 protein levels of CDO KO mice mammary gland (n = 4).(H) Relative expression of β-casein protein in WT, CSAD KO, and CDO KO mammaries (n = 4).(I) Influence of taurine and CSA supplementation on β-casein protein level of CDO KO mice mammary gland (n = 4). Scale bar, 50 μm.

To verify these findings, we compared the relative expression of these proteins by WB. The results indicated that luminal marker K18 and E-Cadh and myoepithelium marker K14 decreased in CDO KO mammary, but increased in CSAD KO mammary ([Figure 8](#fig8){ref-type="fig"}F). CSA, not taurine supplementation, to CDO KO mice increased the relative expression of K18, E-Cadh, and K14 ([Figure 8](#fig8){ref-type="fig"}G).

Relative expression of β-casein was determined to assess the luminal epithelial differentiation in the mammary of the three genotypes of mice by WB. Similarly, loss of CDO led to a relative reduction of β-casein, but loss of CSAD increased β-casein ([Figure 8](#fig8){ref-type="fig"}H). CSA supplementation restored the expression of β-casein ([Figure 8](#fig8){ref-type="fig"}I).

Our results suggested that CDO in the mammary plays a role in retaining lumen character and maintaining luminal cell differentiation via CSA, which is accumulated in CSAD KO mice, but deficient in CDO KO mice.

Loss of CDO Disturbs Cell Proliferation and Cell Apoptosis {#sec2.6}
----------------------------------------------------------

To reveal the mechanism behind the reduction and validity of epithelial cell in CDO KO mammary, we analyzed cell proliferation and cell death of 6-week-old mouse mammary. Ki67 was immunostained to mark proliferating cells, and TUNEL (terminal-deoxynucleotidyl transferase-mediated dUTP nick end labeling) examination was used to label apoptotic cells. The results indicated that loss of CDO led to extreme reduction both in cell proliferation and cell death rate in mature ducts and TEBs ([Figures 9](#fig9){ref-type="fig"}A, 9B, 9E, 9F, 9M, [10](#fig10){ref-type="fig"}A--10C, and 10G). To the contrary, loss of CSAD stimulated cell proliferation in mature ducts ([Figures 9](#fig9){ref-type="fig"}A--9D and 9M) and maintained cell death ([Figures 10](#fig10){ref-type="fig"}A--10C and 10G). When supplemented with CSA, Ki67-positive cells significantly increased in mature duct and TEBs ([Figures 9](#fig9){ref-type="fig"}G, 9H, 9K,9L, and 9N), whereas taurine supplementation showed little effect([Figures 9](#fig9){ref-type="fig"}G--9J, and 9N). Proliferating cell nuclear antigen protein levels, which were detected using WB of mammary lysate, were maintained in accordance with Ki67 ([Figure 9](#fig9){ref-type="fig"}O). Similarly, CSA supplementation to CDO KO females partially rescued the cell death rate ([Figures 10](#fig10){ref-type="fig"}D--10F and 10H). Taurine supplementation showed little effect ([Figures 10](#fig10){ref-type="fig"}D--10F and 10H). These data indicated that CDO plays an important role in regulating cell homeostasis and renewal via CSA and consequently contributes to epithelial morphogenesis in the mammary gland.Figure 9Loss of CDO Resulted in Reduction of Epithelial Cell Proliferation in Mammary Gland, which Was Rescued by CSA Supplementation(A, C, and E) Ki67 label in mature ducts of (A) WT, (C) CSAD KO, and (E) CDO KO mammary glands (n = 4 mammary per treatment).(B, D, and F) Ki67 label in TEBs of (B) WT, (D) CSAD KO, and (F) CDO KO mammary glands (n = 4 mammary per treatment).(G, I, and K) Ki67 label in mature ducts of CDO KO mice mammary gland with (G) NaCl, (I) taurine, or (K) CSA supplementation (n = 4 mammary per treatment).(H, J, and L) Ki67 label in TEBs of CDO KO mice mammary gland with (H) NaCl, (J) taurine, or (L) CSA supplementation (n = 4 mammary per treatment). White arrows point to Ki67-positive cells\' stain in green or merge with DAPI stain, which represents proliferating cells. Scale bar, 50 μm.(M--O) (M) Quantification of Ki67-positive cell percentage in mature ducts and TEBs of WT (n = 4), CSAD KO (n = 4), and CDO KO (n = 4) mammaries. Two different sections were obtained in one sample, and at least three ducts per section were counted to calculate the percentage of Ki67-positive cells in mammary ducts. CSAD KO mammary showed more Ki67-positive cells in mature ducts than WT (WT versus CSAD KO, t test, t-value = −2.69, p = 0.045). CDO KO mammary showed significant decrease in Ki67-positive cells both in mature ducts and TEBs compared with WT (WT versus CDO KO, mature duct: t test, t-value = 5.542, p = 0.003; TEBs: t test, t-value = 9.477, p = 0.000). (N) Quantification of Ki67-positive cell percentage in mature ducts and TEBs of CDO KO mice mammary supplemented with NaCl, taurine, or CSA. CSA supplementation significantly enhanced cell proliferation both in mature ducts and TEBs (NaCl versus CSA, mature duct: t test, t-value = −5.015, p = 0.004; TEBs: t test, t-value = −5.977, p = 0.002) (O) PCNA levels in WT and KO mice and CDO KO mice supplemented with NaCl, taurine, or CSA. \* represents significant difference compared with WT (p \< 0.05), \*\* represents significant difference compared with control (p \< 0.01).Figure 10Loss of CDO Led to Reduction of Cell Death in Mammary GlandTUNEL signals (green) were merged with cell nucleus (Propidium iodide staining in red).(A--C) Cell death in mature ducts of (A) WT, (B) CSAD KO, and (C) CDO KO mammary glands (n = 4 mammary per treatment).(D--F) Cell death in mature ducts of CDO KO mice mammary gland with (D) NaCl, (E) taurine, or (F) CSA supplementation (n = 4 mammary per treatment). White arrow points to TUNEL-positive cells, which represents apoptotic cells. Scale bar, 100 μm.(G) Quantification of TUNEL-positive cell percentage in mature ducts of WT (n = 4), CSAD KO (n = 4), and CDO KO (n = 4) mammaries. CDO KO mammary showed significant decrease in TUNEL-positive cells in mature ducts compared with WT (WT versus CDO KO, t test, t-value = 5.774, p = 0.002).(H) Quantification of TUNEL-positive cell percentage in mature ducts of CDO KO mice mammary supplemented with NaCl, taurine, or CSA. CSA supplementation significantly rescued cell apoptosis in mature ducts (NaCl versus CSA, t test, t-value = −6.132, p = 0.002). \*\* represents significant difference compared with WT or control (p \< 0.01).

Discussion {#sec3}
==========

In this study, we discovered that CDO, a key enzyme in cysteine oxidative metabolism and taurine biosynthesis, regulates mammary epithelial morphogenesis through its direct downstream metabolite CSA. It has been reported that the offspring of CDO KO females could not survive; however, the mechanism is unknown ([@bib43]). Mammary epithelial morphogenesis is the base of organotypic growth of mammary parenchyma and important for functional formation ([@bib21], [@bib28], [@bib47]). As we know, mammary gland development is a complex process with a variety of statuses in different developmental stages. In this study, we initially found that CDO was enriched in the mammary gland of branching morphogenesis stages, but was lacking in alveolus stages. We confirmed that loss of CDO led to severe defects in mammary branching morphogenesis, ductal elongation, and poor lactation outcome. We provided evidence that the death of the offspring resulted from the insufficient lactation of CDO KO mothers.

Mammary branching morphogenesis and elongation are predominantly active after onset of puberty, which largely depends on pituitary and ovarian hormones, such as GH, PRL, estrogen, and progesterone ([@bib20], [@bib47]). Our data indicated that CDO is abundant in virgin mammary gland, but is very little in endocrine organs including hypothalamus, pituitary, and ovary. Adult CDO KO females are fertile, and pituitary produced GH and PRL properly in CDO KO females. The results of our mammary-gland-specific CDO expression and KO experiments suggest that the process of CDO regulating mammary development is independent of pituitary and ovarian endocrine action.

In this work, we revealed a novel role for CDO in regulating mammary ductal epithelial morphogenesis and lactation function. In addition, it is interesting that CDO is enriched in typical tree-like developmental organs including mammary gland, lung, and kidney, implying that it may be a common factor in regulating the organ branching morphogenesis and functional formation. We also found more large alveoli in the lung of adult CDO KO mice, resulting in decreased alveolar surface area. It may be a consequence of insufficient lung branching morphogenesis.

CDO and CSAD are rate-limiting enzymes in taurine synthesis. Both CDO KO mice and CSAD KO mice exhibited systematic taurine deficiency. However, CSAD KO females did not show the defect in mammary development. On the contrary, CSAD KO mammary possessed more milk production alveolar unit compared with WT mice during lactation stage. It suggests that taurine is not the key molecule that supports mammary development. In this work, we provide evidences that CSA greatly rescued the mammary dysplasia resulting from loss of CDO and that it also significantly contributed to mammary ductal growth in WT mice. CSA is the direct downstream product of CDO, and it is also the substrate of CSAD ([@bib30], [@bib40]). Therefore loss of CDO led to CSA deficiency, but loss of CSAD resulted in CSA accumulation in cells. It was confirmed by both serum and mammary CSA assays. Our results showed that loss of CSAD exhibited an effect similar to CSA supplementation. Known as a precursor of taurine biosynthesis, CSA has been described to exist in the central nervous system as a neurotransmitter ([@bib2], [@bib35]). CSA is able to enter and exit from cells through interaction with special receptors on the cell membrane ([@bib1], [@bib15], [@bib34]). However, understanding of the biological functions of CSA is still rather limited. Here, we provide evidences that CSA has positive effect on promoting mammary gland development, which would be a potential solution for mammary dysplasia in human and farm animals.

Mammary gland has been utilized to study the general mechanisms of epithelial morphogenesis as well as to understand the more pressing issue of mammary tumorigenesis ([@bib5], [@bib12], [@bib25]). The increased incidence of breast tumors in nulliparous women may be related to the low degree of differentiation of mammary epithelial cells ([@bib36]). Here we showed that the CDO is an important regulator maintaining luminal epithelium character and luminal epithelial cell differentiation via CSA in the mammary gland. CDO KO mammary displayed less differentiated luminal epithelial cells with the characteristics of myoepithelium. We have verified that the protein level of epithelial cell markers decreased in CDO KO mammary, which can be upregulated by CSA. β-casein, a luminal epithelial differentiation marker, reduced in CDO KO mammary, which can be upregulated by CSA. Recent studies have revealed that CDO inactivation is associated with the occurrence of various cancers ([@bib3], [@bib16]). Loss of organization is associated with cancer ([@bib4]). In addition, we showed a disorganized epithelium in mammary ducts and higher risk of developing breast tumors in CDO KO mice older than 12 weeks. It suggests that CDO has an important role in maintaining lumen and epithelial cell differentiation via CSA, which has important implications for epithelial cell fate determination and pathogenesis of breast cancer.

Mammary development involves epithelial cell proliferation and apoptosis. After onset of puberty, mammary development is driven by the highly proliferative TEBs, which actuate ductal elongation and branching in the surrounding fat pad until the ducts reach the edge limits of the fat pad ([@bib12], [@bib28], [@bib29]). Epithelial cell apoptosis is vital in mammary development and functional formation ([@bib9], [@bib14]). In the present study, we showed evidences that CDO maintained both levels of epithelial cell proliferation and apoptosis. Importantly, loss of CDO dramatically reduced both cell proliferation and apoptosis. The unregulated processes of cell proliferation and apoptosis can be rescued by CSA supplementation, which has an implication in organ regeneration and cell renewal.

In conclusion, our study demonstrated that CDO plays important roles in regulating mammary epithelial cell differentiation, proliferation, and apoptosis, through which mammary epithelial morphogenesis is controlled. Importantly, instead of taurine, the direct downstream metabolite of CDO CSA was heavily involved in these processes. Our findings have led to appreciative discovery of the relationship between cysteine metabolism and mammary epithelial morphogenesis and have provided insights into the organ morphogenesis and implications in tumorigenesis.

Limitations of the Study {#sec3.1}
------------------------

In this study we described that CDO regulates mammary epithelial morphogenesis via CSA, which maintains epithelial cell differentiation, proliferation, and apoptosis. However, the mechanisms of CSA\'s action are not fully demonstrated in this study. Our data suggest that CDO may be a common factor in regulating the organ branching morphogenesis and functional formation. However, these inferences need more experiments to be clarified.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods, Figures S1--S7, and Tables S1--S5

We thank Dr. Hefang Xie for her valuable comments on our manuscript. This work was supported by Chongqing Research Program of Basic Research and Frontier Technology (cstc2016jcyjA0386), Fundamental Research Funds for the Central Universities (XDJK2016C050), Fundamental Research Funds for the Central Universities (No.XDJK2018B024), and Doctoral Funds of Southwest University (2016).

Author Contributions {#sec6}
====================

J.Z., and A.L. conceived this study. J.Z and Y. H. designed the experiments. J.Z., X.M., G.Y., H.L., P.F., and B.Q. performed the experiments. Y.Z, S.Y, Q.S, and G.Z analyzed the data. J.Z., Y.Z, and Q.S. wrote the manuscript.

Declaration of Interests {#sec7}
========================

A patent application has been filed related to this work. The authors declare no competing interests.

Supplemental Information can be found online at [https://doi.org/10.1016/j.isci.2019.02.011](10.1016/j.isci.2019.02.011){#intref0010}.

[^1]: Lead Contact
